
You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX. Talk to your health care provider if you experience symptoms of an allergic reaction to FASLODEX, which may include itching or hives; swelling of your face, lips, tongue, or throat; and trouble breathing.
Before receiving FASLODEX, tell your health care provider about all of your medical conditions, including if you:
Tell your health care provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FASLODEX may affect the way other medicines work, and other medicines may affect how FASLODEX works.
FASLODEX is administered by your health care provider as an injection into the muscle of each buttock. Your health care provider may change your dose of FASLODEX if needed.
FASLODEX may cause injection site–related nerve damage. Call your health care provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness, tingling, or weakness.
Common side effects of FASLODEX include injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath; constipation; increased liver enzymes; and diarrhea.
Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your health care provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088.
FASLODEX is a prescription medicine used to treat women with:
When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.
When FASLODEX is used in combination with abemaciclib, please also see the abemaciclib Patient Information.
It is not known if FASLODEX is safe and effective in children or in people with severe liver problems.
Please see FASLODEX Prescribing Information with Patient Information.
You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX... Read More
Whether you and your doctor are considering FASLODEX, or you are already receiving FASLODEX, it’s important to understand how your medicine works—and what that means for your advanced breast cancer treatment.
FASLODEX is a prescription medicine used to treat women with:
Most breast cancers are HR-positive. FASLODEX can be used in HR -positive breast cancer because it is designed to target the estrogen receptor, which is an HR that is present in this type of breast cancer.
FASLODEX may be an appropriate choice for you whether it is used alone or with either IBRANCE or Verzenio. Talk to your doctor about which option may be best for you.
If you have HR-positive, HER2-negative advanced breast cancer and have not been given endocrine therapy for advanced breast cancer, and have gone through menopause, FASLODEX may be an option for your first hormonal therapy. Based on the results of a clinical study called FALCON, FASLODEX can be used instead of an aromatase inhibitor called anastrozole.
If you have been given endocrine therapy for advanced breast cancer and you have HR-positive, HER2-negative advanced breast cancer, FASLODEX with Verzenio may be a treatment option available to you.
Now, let’s break down some of those terms. Understanding these terms can help you take on more of an active role in your treatment.
Breast cancer can be either HR-positive or HR-negative. HR-positive breast cancer uses proteins and hormones to support the growth or spread of the cancer. HR-negative breast cancer does not use hormones to grow.
HR-positive cancer cells depend on HRs, such as estrogen receptors (see definition below) or progesterone receptors (a different type of receptor), to grow. Your doctor may also use the term estrogen receptor-positive.
Ask your doctor if you are not sure what your HR status is.
HER2 is a type of specialized receiver that can play a role in cancer growth.
Cancer cells can be either HER2-positive or HER2-negative.
HER2-negative cancer cells may grow more slowly than cells with a high amount of HER2.
Ask your doctor if you are not sure what your HER2 status is.
If you have HR-positive metastatic breast cancer (see definition above), this means that the estrogen receptor—pictured near this text—may play a role in your cancer.
The estrogen receptor, which is the most common type of HR, can cause cancer to grow in several ways, explained below.
FASLODEX can connect with estrogen receptors much like how a baseball connects with a glove: by fitting into a specialized receiver. When FASLODEX fits into the estrogen receptor, it may be able to slow cancer growth by blocking* estrogen receptor activation.
*FASLODEX does not block 100% of estrogen receptors.
HR-positive breast cancer relies on proteins and hormones inside your body to grow. The estrogen receptor is one of these proteins. It can cause cancer growth in several ways, such as by:
Connecting with estrogen, which is a hormone that can send signals leading to the spread of cancer.
When FASLODEX connects with the estrogen receptor, the estrogen receptor’s ability to connect with estrogen is reduced.
Sending signals that do not rely on estrogen inside cancer cells.
Breast cancer doesn’t always need estrogen to grow. Sometimes, the estrogen receptor can cause cancer growth without estrogen. FASLODEX works on the estrogen receptor rather than on estrogen.
Participating in the cell cycle, which leads to tumor cell division.
Cancer grows when tumor cells divide and multiply. The estrogen receptor can start this process—but FASLODEX may be able to get in the way of the estrogen receptor.
Learn more about how FASLODEX works
FASLODEX acts in many ways. Below, you can learn more about how FASLODEX works on the estrogen receptor—and what that means for your treatment.
Select an option below to learn more about the impact FASLODEX can have on HR-positive metastatic breast cancer growth. FASLODEX is the only approved hormonal medicine that has been shown to interact with the estrogen receptor in these ways.
When FASLODEX connects with estrogen receptors,† those estrogen receptors can react by:
†As demonstrated in laboratory studies.
FASLODEX impacts the way estrogen receptors work by connecting to them.
Estrogen receptors that are connected to FASLODEX have a reduced ability to activate or communicate with estrogen. Inactive estrogen receptors cannot participate in cancer growth.
FASLODEX interferes with estrogen receptors’ ability to activate.
‡FASLODEX does not block 100% of estrogen receptors.
Estrogen receptors that are connected to FASLODEX break down quickly, resulting in fewer estrogen receptors in cancer cells.
Broken down estrogen receptors cannot participate in the process of cancer growth.
When FASLODEX decreases the number of available estrogen receptors in breast cancer cells, estrogen receptors’ ability to cause cancer cells to divide and multiply is impacted.
FASLODEX is associated with a decrease in Ki67, a marker of cancer growth.
Having fewer available estrogen receptors makes it more difficult for estrogen receptors to support cancer growth.
You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX. Talk to your health care provider if you experience symptoms of an allergic reaction to FASLODEX, which may include itching or hives; swelling of your face, lips, tongue, or throat; and trouble breathing.
Before receiving FASLODEX, tell your health care provider about all of your medical conditions, including if you:
Tell your health care provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FASLODEX may affect the way other medicines work, and other medicines may affect how FASLODEX works.
FASLODEX is administered by your health care provider as an injection into the muscle of each buttock. Your health care provider may change your dose of FASLODEX if needed.
FASLODEX may cause serious side effects, including injection site–related nerve damage. Call your health care provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness, tingling, or weakness.
Common side effects of FASLODEX include injection site pain; nausea; muscle, joint, and bone pain; headache; back pain; tiredness; pain in arms, hands, legs or feet; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath; constipation; increased liver enzymes; and diarrhea.
Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your health care provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088.
FASLODEX is a prescription medicine used to treat advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic).
FASLODEX may be used alone, if you have gone through menopause, and your advanced breast cancer is:
or
FASLODEX may be used in combination with ribociclib, if you have gone through menopause, and your advanced or metastatic breast cancer is HR-positive and HER2-negative, and has not been previously treated with endocrine therapy or has progressed after endocrine therapy.
FASLODEX may be used in combination with palbociclib or abemaciclib if your advanced or metastatic breast cancer is HR-positive and HER2-negative, and has progressed after endocrine therapy.
When FASLODEX is used in combination with palbociclib, abemaciclib or ribociclib, also read the Patient Information for the prescribed product.
It is not known if FASLODEX is safe and effective in children or in people with severe liver problems.
Please see FASLODEX Prescribing Information with Patient Information.
You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX. Talk to your health care provider if you experience symptoms of an allergic reaction to FASLODEX, which may include itching or hives; swelling of your face, lips, tongue, or throat; and trouble breathing.
Before receiving FASLODEX, tell your health care provider about all of your medical conditions, including if you:
Tell your health care provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FASLODEX may affect the way other medicines work, and other medicines may affect how FASLODEX works.
FASLODEX is administered by your health care provider as an injection into the muscle of each buttock. Your health care provider may change your dose of FASLODEX if needed.
FASLODEX may cause serious side effects, including injection site–related nerve damage. Call your health care provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness, tingling, or weakness.
Common side effects of FASLODEX include injection site pain; nausea; muscle, joint, and bone pain; headache; back pain; tiredness; pain in arms, hands, legs or feet; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath; constipation; increased liver enzymes; and diarrhea.
Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your health care provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088.
FASLODEX is a prescription medicine used to treat advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic).
FASLODEX may be used alone, if you have gone through menopause, and your advanced breast cancer is:
or
FASLODEX may be used in combination with ribociclib, if you have gone through menopause, and your advanced or metastatic breast cancer is HR-positive and HER2-negative, and has not been previously treated with endocrine therapy or has progressed after endocrine therapy.
FASLODEX may be used in combination with palbociclib or abemaciclib if your advanced or metastatic breast cancer is HR-positive and HER2-negative, and has progressed after endocrine therapy.
When FASLODEX is used in combination with palbociclib, abemaciclib or ribociclib, also read the Patient Information for the prescribed product.
It is not known if FASLODEX is safe and effective in children or in people with severe liver problems.
Please see FASLODEX Prescribing Information with Patient Information.